Galecto, Inc. Information

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Website	http://www.galecto.com
Ticker	GLTO
Revenue	$13.5 million
Funding	$281.5 million
Employees	11 (9 on RocketReach)
Founded	2011
Address	3 Ole Maaloes Vej, Copenhagen DK-2200, DK
Phone	+45 70 70 52 10
Industry	Pharmaceuticals, Biotechnology Research, Biotechnology, Drug Discovery, Galectin modulators, Healthcare, Science and Engineering, Galectin-3 inhibitors, Health Care, Fibrosis treatment
Web Rank	9 Million
Keywords	Biotechnology, Small Molecule Therapeutics, Fibrosis Treatment, Inflammation Treatment, Cancer Treatment, Clinical Stage, Drug Development, Novel Therapeutics, Targeted Therapy, Therapeutic Development, Clinical Trials, Pharmaceutical, Drug Discovery, Molecular Medicine, Pharmaceutical Research, Biologics, Disease Treatment, Biomedical Research, Life Sciences, Health Technology
Competitors	Vertex Pharmaceuticals, Lengo Therapeutics, Galapagos, Karyopharm Therapeutics Inc., Zymeworks Inc., Reata Pharmaceuticals, Inc., Molecular Partners, Medigene AG, Sierra Oncology, Apexigen +35 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies
NAICS	NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies